Metraipolis › archive › dc_bcdb2cfebbe2

Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis — Europe PMC PMID:40918455

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40918455
DOI: 10.32604/or.2025.065029
License (as archived): solo-consultazione
Archived: 2026-11-10T07:21:15.092Z
SHA-256 of the archived text: 461d96cc3b7355ef5b77b590414b1e3e45180e27faebc1cf1ffa41d9fe715701
Stable URL of this page: https://metraipolis.com/documento/dc_bcdb2cfebbe2

How to cite

Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis — Europe PMC PMID:40918455 — Europe PMC (en), https://europepmc.org/article/MED/40918455 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bcdb2cfebbe2 (Metraipolis archive dc_bcdb2cfebbe2, sha256 461d96cc3b7355ef5b77b590414b1e3e45180e27faebc1cf1ffa41d9fe715701)

BibTeX

@misc{dcbcdb2cfebbe2,
  title = {Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis — Europe PMC PMID:40918455},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40918455},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bcdb2cfebbe2; sha256 461d96cc3b7355ef5b77b590414b1e3e45180e27faebc1cf1ffa41d9fe715701},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40918455. Agents can read the archived copy with the MCP tool read_document.